文献速递神经肿瘤

弥漫性中线胶质瘤的预后因素分析

Prognostic factors analysis of diffuse midline glioma.
PubMed 文献 · J Neurooncol · 2024-02-21

本研究回顾性分析64例接受放疗的弥漫性中线胶质瘤患者,其中41例行手术切除、23例行活检,所有患者接受术后放疗。全组中位生存时间33.3个月,1年、2年、3年总生存率分别为92.9%、75.4%、45.0%。单因素和多因素分析提示年龄较大患者预后较好,患者年龄是接受放疗的弥漫性中线胶质瘤的独立预后因素。

要点

  • 全组中位生存时间33.3个月,1年、2年、3年总生存率分别为92.9%、75.4%、45.0%。
  • 单因素和多因素分析提示年龄较大患者预后较好。
  • 患者年龄是接受放疗的弥漫性中线胶质瘤的独立预后因素。

核心结论

  • 患者年龄是接受放疗的弥漫性中线胶质瘤的独立预后因素。

研究设计与样本

  • 回顾性分析2018年1月至2022年11月收治的64例经病理诊断为弥漫性中线胶质瘤的患者,其中41例行手术切除、23例行活检,所有患者接受术后放疗。

主要发现

  • 全组中位生存时间为33.3个月,1年、2年、3年总生存率分别为92.9%、75.4%、45.0%。
  • 单因素和多因素分析提示年龄较大患者预后较好。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This study retrospectively analyzes cases of diffuse midline glioma treated with radiotherapy, with the aim of investigating the prognosis of the tumor and its influencing factors. METHODS: From January 2018 to November 2022, we treated 64 patients who were pathologically diagnosed with diffuse midline glioma. Among them, 41 underwent surgical resection, and 23 underwent biopsy procedures. All patients received postoperative radiotherapy. We followed up with the patients to determine the overall survival rate and conducted univariate and multivariate analyses on relevant indicators. RESULTS: The median survival time for the entire patient group was 33.3 months, with overall survival rates of 92.9%, 75.4%, and 45.0% at 1 year, 2 years, and 3 years, respectively. Univariate and multivariate analyses indicated that older patients had a better prognosis. CONCLUSION: Patient age is an independent prognostic factor for patients with diffuse midline glioma undergoing radiation therapy.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Jiang J, Li WB, Xiao SW, et al. Prognostic factors analysis of diffuse midline glioma. J Neurooncol. 2024. PMID: 38381257. doi:10.1007/s11060-024-04605-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。